journal article·2023-12-31Open access

Advances in screening and diagnostic lab-on-chip tools for gynaecological cancers – a review

Sadeka Nujhat, Hannah S. Leese, Mirella Di Lorenzo, Rebecca Bowen, Sandhya Moise

Abstract

Gynaecological cancers are a major global health concern due to the lack of effective screening programmes for ovarian and endometrial cancer, for example, and variable access to vaccination and screening tests for cervical cancer in many countries. Recent research on portable and cost-effective lab-on-a-chip (LoC) technologies show promise for mass screening and diagnostic procedures for gynaecological cancers. However, most LoCs for gynaecological cancer are still in development, with a need to establish and clinically validate factors such as the type of biomarker, sample and method of detection, before patient use. Multiplex approaches, detecting a panel of gynaecological biomarkers in a single LoC, offer potential for more reliable diagnosis. This review highlights the current research on LoCs for gynaecological cancer screening and diagnosis, emphasizing the need for further research and validation prior to their widespread adoption in clinical practice.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Biosensing Techniques and Applications · Nanowire Synthesis and Applications · GaN-based semiconductor devices and materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, University of Bath, Bath, UK

Centre for Bioengineering and Biomedical Technologies (CBio), University of Bath, Bath, UK

Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

Department of Life Sciences, University of Bath, Bath, UK

Centre for Therapeutic Innovation (CTI), University of Bath, Bath, UK

Funding

University of Bath’s University Research Studentship Award

References (83)

Show source-provided references
1. 10.1016/j.soncn.2019.03.00210.1016/j.soncn.2019.03.002 ↗
2. 10.1111/ajo.1323710.1111/ajo.13237 ↗
3. 10.3399/bjgp13X67163210.3399/bjgp13X671632 ↗
4. 10.1002/ijc.3376310.1002/ijc.33763 ↗
5. Cancer Research UK. Early diagnosis data hub; 2022. Available from: https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/
6. 10.1016/j.soncn.2019.02.00110.1016/j.soncn.2019.02.001 ↗
7. 10.1097/AOG.000000000000258010.1097/AOG.0000000000002580 ↗
8. Penny SM. Ovarian cancer: an overview. Radiol Technol. 2020;91(6):561–575.
9. 10.1016/S0140-6736(13)60022-710.1016/S0140-6736(13)60022-7 ↗
10. 10.3390/v1012072910.3390/v10120729 ↗
11. 10.7759/cureus.3131210.7759/cureus.31312 ↗
12. 10.2174/157488711066615092311295810.2174/1574887110666150923112958 ↗
13. 10.1016/j.ogc.2018.09.00810.1016/j.ogc.2018.09.008 ↗
14. 10.1038/bjc.2013.41210.1038/bjc.2013.412 ↗
15. 10.1002/ijgo.1387110.1002/ijgo.13871 ↗
16. 10.1016/j.ogc.2021.06.00110.1016/j.ogc.2021.06.001 ↗
17. 10.1016/j.soncn.2017.02.00210.1016/j.soncn.2017.02.002 ↗
18. 10.4103/ijc.IJC_418_1910.4103/ijc.IJC_418_19 ↗
19. 10.3109/08958378.2014.95593210.3109/08958378.2014.955932 ↗
20. Cancer Research UK. Getting diagnosed with breast cancer; 2023 [cited 2023 Sep 3].
21. 10.5888/pcd15.17046510.5888/pcd15.170465 ↗
22. 10.1309/AJCP03HUQYZMWATP10.1309/AJCP03HUQYZMWATP ↗
23. 10.1038/nprot.2006.23610.1038/nprot.2006.236 ↗
24. Westra WH. Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. Oral Oncol. 2014;50(9):771–779; Chatzistamatiou K, Moysiadis T, Moschaki V, et al. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecol Oncol. 2016;142(1):120–127; Bebyn MG, Sledzinska P, Wojtysiak J, et al. HPV RNA and DNA testing in Polish women screened for cervical cancer – a single oncological center study. Eur J Obstet Gynecol Reprod Biol. 2022;268:129–134.10.1016/j.oraloncology.2014.05.004 ↗
25. 10.1016/j.bpobgyn.2020.02.01010.1016/j.bpobgyn.2020.02.010 ↗
26. 10.1177/10732748090160010310.1177/107327480901600103 ↗
27. 10.1186/s12889-020-08545-410.1186/s12889-020-08545-4 ↗
28. 10.20471/acc.2021.60.01.0810.20471/acc.2021.60.01.08 ↗
29. 10.1186/s13048-019-0503-710.1186/s13048-019-0503-7 ↗
30. Haga Y, Sakamoto K, Egami H, et al. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci. 1986;292(1):25–29.10.1097/00000441-198607000-00005 ↗
31. 10.1055/s-0040-172254710.1055/s-0040-1722547 ↗
32. 10.7759/cureus.675310.7759/cureus.6753 ↗
33. Burness JV, Schroeder JM, Warren JB. Cervical colposcopy: indications and risk assessment. Am Fam Physician. 2020;102(1):39–48.
34. 10.1016/j.ijgo.2011.10.02210.1016/j.ijgo.2011.10.022 ↗
35. 10.3390/s9060440710.3390/s90604407 ↗
36. 10.1007/10_2020_12710.1007/10_2020_127 ↗
37. 10.1186/s40580-019-0173-610.1186/s40580-019-0173-6 ↗
38. 10.1021/acs.analchem.9b0392010.1021/acs.analchem.9b03920 ↗
39. 10.1021/acs.analchem.1c0498810.1021/acs.analchem.1c04988 ↗
40. 10.1039/c5lc01117e10.1039/c5lc01117e ↗
41. Sanjay ST, Fu G, Dou M, et al. Biomarker detection for disease diagnosis using cost-effective microfluidic platforms. Analyst. 2015;140(21):7062–7081; Gubala V, Harris LF, Ricco AJ, et al. Point of care diagnostics: status and future. Anal Chem. 2012;84(2):487–515.10.1039/C5AN00780A ↗
42. 10.1007/s13534-013-0094-y10.1007/s13534-013-0094-y ↗
43. 10.1177/193229682095875410.1177/1932296820958754 ↗
44. 10.1007/978-3-031-04039-9_1310.1007/978-3-031-04039-9_13 ↗
45. 10.1016/j.ijbiomac.2019.07.10910.1016/j.ijbiomac.2019.07.109 ↗
46. 10.1016/j.colsurfb.2020.11080810.1016/j.colsurfb.2020.110808 ↗
47. 10.3892/or.2016.523510.3892/or.2016.5235 ↗
48. 10.1021/acsami.1c0475210.1021/acsami.1c04752 ↗
49. 10.1016/j.bios.2016.04.06210.1016/j.bios.2016.04.062 ↗
50. 10.1016/j.cca.2014.02.00310.1016/j.cca.2014.02.003 ↗
51. 10.3390/mi1203026310.3390/mi12030263 ↗
52. 10.12688/f1000research.6395.110.12688/f1000research.6395.1 ↗
53. 10.1039/c5lc00636h10.1039/c5lc00636h ↗
54. 10.1039/d0ra10200h10.1039/d0ra10200h ↗
55. 10.1200/JCO.2011.39.854510.1200/JCO.2011.39.8545 ↗
56. 10.1177/175883401771499310.1177/1758834017714993 ↗
57. 10.31557/APJCP.2019.20.4.108110.31557/APJCP.2019.20.4.1081 ↗
58. 10.1038/s41571-020-00457-x10.1038/s41571-020-00457-x ↗
59. Riethdorf S, O'Flaherty L, Hille C, et al. Clinical applications of the CellSearch platform in cancer patients. Adv Drug Deliv Rev. 2018;125:102–121; Millner LM, Linder MW, Valdes R Jr. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013;43(3):295–304.10.1016/j.addr.2018.01.011 ↗
60. Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176(1–2):98–112.e14; Pineiro R, Martinez-Pena I, Lopez-Lopez R. Relevance of CTC clusters in breast cancer metastasis. Adv Exp Med Biol. 2020;1220:93–115.10.1016/j.cell.2018.11.046 ↗
61. 10.1111/1471-0528.1661810.1111/1471-0528.16618 ↗
62. 10.1080/19420862.2021.197813010.1080/19420862.2021.1978130 ↗
63. 10.1063/1.481693410.1063/1.4816934 ↗
64. 10.1016/j.bios.2011.06.03410.1016/j.bios.2011.06.034 ↗
65. 10.1515/ntrev-2016-001410.1515/ntrev-2016-0014 ↗
66. 10.1186/s13045-020-00987-y10.1186/s13045-020-00987-y ↗
67. Costanzo H, Gooch J, Frascione N. Nanomaterials for optical biosensors in forensic analysis. Talanta. 2023;253:123945; Hu X, Zhang Y, Ding T, et al. Multifunctional gold nanoparticles: a novel nanomaterial for various medical applications and biological activities. Front Bioeng Biotechnol. 2020;8:990.10.1016/j.talanta.2022.123945 ↗
68. 10.1002/wnan.171610.1002/wnan.1716 ↗
69. 10.1186/s40880-017-0235-210.1186/s40880-017-0235-2 ↗
70. 10.1007/s13534-021-00204-w10.1007/s13534-021-00204-w ↗
71. 10.1111/cod.1363810.1111/cod.13638 ↗
72. 10.1080/14789450.2016.119065110.1080/14789450.2016.1190651 ↗
73. 10.1088/1361-6439/aae01610.1088/1361-6439/aae016 ↗
74. 10.3390/s1807203810.3390/s18072038 ↗
75. Shreffler J Huecker MR. Diagnostic testing accuracy: sensitivity specificity predictive values and likelihood ratios. StatPearls; 2023.
76. 10.1021/acs.bioconjchem.8b0059210.1021/acs.bioconjchem.8b00592 ↗
77. 10.1063/1.500070710.1063/1.5000707 ↗
78. 10.3390/mi1204034710.3390/mi12040347 ↗
79. 10.1007/s00604-019-3594-310.1007/s00604-019-3594-3 ↗
80. 10.3390/s12091271010.3390/s120912710 ↗
81. 10.1002/jemt.2252910.1002/jemt.22529 ↗
82. 10.3390/mi909046110.3390/mi9090461 ↗
83. 10.3390/bios1211102310.3390/bios12111023 ↗